PT - JOURNAL ARTICLE AU - Juanjuan Zhao AU - Quan Yuan AU - Haiyan Wang AU - Wei Liu AU - Xuejiao Liao AU - Yingying Su AU - Xin Wang AU - Jing Yuan AU - Tingdong Li AU - Jinxiu Li AU - Shen Qian AU - Congming Hong AU - Fuxiang Wang AU - Yingxia Liu AU - Zhaoqin Wang AU - Qing He AU - Zhiyong Li AU - Bin He AU - Tianying Zhang AU - Shengxiang Ge AU - Lei Liu AU - Jun Zhang AU - Ningshao Xia AU - Zheng Zhang TI - Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019 AID - 10.1101/2020.03.02.20030189 DP - 2020 Jan 01 TA - medRxiv PG - 2020.03.02.20030189 4099 - http://medrxiv.org/content/early/2020/03/02/2020.03.02.20030189.short 4100 - http://medrxiv.org/content/early/2020/03/02/2020.03.02.20030189.full AB - Background The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patient remains largely unknown, and the clinical values of antibody testing have not been fully demonstrated.Methods A total of 173 patients with confirmed SARS-CoV-2 infection were enrolled. Their serial plasma samples (n = 535) collected during the hospitalization period were tested for total antibodies (Ab), IgM and IgG against SARS-CoV-2 using immunoassays. The dynamics of antibodies with the progress and severity of disease was analyzed.Results Among 173 patients, the seroconversion rate for Ab, IgM and IgG was 93.1% (161/173), 82.7% (143/173) and 64.7% (112/173), respectively. Twelve patients who had not seroconverted were those only blood samples at the early stage of illness were collected. The seroconversion sequentially appeared for Ab, IgM and then IgG, with a median time of 11, 12 and 14 days, respectively. The presence of antibodies was < 40% among patients in the first 7 days of illness, and then rapidly increased to 100.0%, 94.3% and 79.8% for Ab, IgM and IgG respectively since day 15 after onset. In contrast, the positive rate of RNA decreased from 66.7% (58/87) in samples collected before day 7 to 45.5% (25/55) during days 15 to 39. Combining RNA and antibody detections significantly improved the sensitivity of pathogenic diagnosis for COVID-19 patients (p < 0.001), even in early phase of 1-week since onset (p = 0.007). Moreover, a higher titer of Ab was independently associated with a worse clinical classification (p = 0.006).Conclusions The antibody detection offers vital clinical information during the course of SARS-CoV-2 infection. The findings provide strong empirical support for the routine application of serological testing in the diagnosis and management of COVID-19 patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNot a study of clinical trialFunding StatementThis study was supported by Bill & Melinda Gates Foundation.The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe will share individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices). Also redacted Study Protocol and Statistical Analysis Plan will be shared. The data will be available beginning 6 months after the major findings from the final analysis of the study were published, ending 2 years later. The data will be shared with investigators whose proposed use of the data has been approved by an independent review committee identified for individual participant data meta-analysis. Proposals should be directed to zhangzheng1975@aliyun.com or zhangj@xmu.edu.cn. To gain access, data requestors will need to sign a data access agreement.